ProCE Banner Activity

Combination Therapy With TROP2-Targeted Antibody–Drug Conjugates and Immunotherapy in Advanced/Metastatic NSCLC

Clinical Thought

Get up to date on strategies combining TROP2 ADCs with immune checkpoint inhibitor therapy for the treatment of advanced/metastatic NSCLC in this commentary by Benjamin Levy, MD, including review of the latest clinical evidence and ongoing clinical trials to consider for your patients.

Released: May 03, 2023

Share

Faculty

Benjamin Levy

Benjamin Levy, MD

Associate Professor
Johns Hopkins School of Medicine
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Disclosure

Primary Author

Benjamin Levy, MD

Associate Professor
Johns Hopkins School of Medicine
Baltimore, Maryland

Benjamin Levy, MD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Janssen, Mirati, Pfizer, Merck, Novartis.